STOCK TITAN

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Phathom Pharmaceuticals to participate in investor conferences
Positive
  • None.
Negative
  • None.

FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences:

  • Morgan Stanley 21st Annual Global Healthcare Conference in New York City. Management will participate in one-on-one meetings on September 12, 2023.

  • H.C. Wainwright 25th Annual Global Investment Conference in New York City. Management will participate in a fireside chat on Wednesday, September 13, 2023 at 2:30 p.m. EDT and one-on-one meetings throughout the day.

To access the live webcast and archived recording of the fireside chat, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. The recording will be available for 90 days following the event.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). For more information about Phathom, visit the Company’s website at www.phathompharma.com and follow the Company on LinkedIn and Twitter.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2023 Phathom Pharmaceuticals. All rights reserved.


Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

PHAT Rankings

PHAT Latest News

PHAT Stock Data

651.98M
51.12M
7.7%
109.32%
25.54%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FLORHAM PARK